PuSH - Publication Server of Helmholtz Zentrum München

90 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
21.
Vogel, H.* et al.: A collective diabetes cross in combination with a computational framework to dissect the genetics of human obesity and Type 2 diabetes. Hum. Mol. Genet. 27, 3099-3112 (2018)
22.
Clemmensen, C. et al.: Gut-brain cross-talk in metabolic control. Cell 168, 758-774 (2017)
23.
Collden, G. ; Tschöp, M.H. & Müller, T.D.: Therapeutic potential of targeting the ghrelin pathway. Int. J. Mol. Sci. 18:798 (2017)
24.
Fischer, K. et al.: Alternatively activated macrophages do not synthesize catecholamines or contribute to adipose tissue adaptive thermogenesis. Nat. Med. 23, 623-630 (2017)
25.
Götz, A. ; Jall, S. ; Tschöp, M.H. & Müller, T.D.: Inkretinbasierte Medikamente zur Diabetes- und Adipositastherapie. Entwicklungsperspektiven.   Diabetologe 13, 505–513 (2017)
26.
Hinney, A.* et al.: Evidence for three genetic loci involved in both anorexia nervosa risk and variation of body mass index. Mol. Psychiatry 22, 192-201 (2017)
27.
Hinney, A.* et al.: Evidence for three genetic loci involved in both anorexia nervosa risk and variation of body mass index (vol 22, pg 192, 2017). Mol. Psychiatry 22, 321-322 (2017)
28.
Jall, S. et al.: Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Mol. Metab. 6, 440-446 (2017)
29.
Kleinert, M. et al.: Emerging poly-agonists for obesity and type 2 diabetes. Obesity 25, 1647-1649 (2017)
30.
Müller, T.D. ; Finan, B. ; Clemmensen, C. ; DiMarchi, R.D. & Tschöp, M.H.: The new biology and pharmacology of glucagon. Physiol. Rev. 97, 721-766 (2017)
31.
Pfuhlmann, K. et al.: Dual specificity phosphatase 6 deficiency is associated with impaired systemic glucose tolerance and reversible weight retardation in mice. PLoS ONE 12:e0183488 (2017)
32.
Quarta, C. et al.: Molecular integration of incretin and glucocorticoid action reverses immunometabolic dysfunction and obesity. Cell Metab. 26, 620-632.e6 (2017)
33.
Sánchez-Garrido, M.A. et al.: GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia 60, 1851–1861 (2017)
34.
Clemmensen, C. ; Müller, T.D. ; Finan, B. ; Tschöp, M.H. & DiMarchi, R.*: Current and emerging treatment options in diabetes care. Handb. Exp. Pharmacol. 233, 437-459 (2016)
35.
de Angelis, M. et al.: Determination of thyroid hormones in mouse tissues by isotope-dilution microflow liquid chromatography-mass spectrometry method. J. Chromatogr. B 1033-1034, 413-420 (2016)
36.
Finan, B. ; Müller, T.D. ; Clemmensen, C. ; Perez-Tilve, D.* & Tschöp, M.H.: Reappraisal of GIP pharmacology for metabolic diseases. Trends Mol. Med. 22, 359-376 (2016)
37.
Finan, B. et al.: Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic Impact for metabolic disease. Cell 167, 843-857.e14 (2016)
38.
Gomes, I.* et al.: Identification of GPR83 as the receptor for the neuroendocrine peptide PEN. Sci. Signal. 9:ra43 (2016)
39.
Kabra, D.G. et al.: Hypothalamic leptin action is mediated by histone deacetylase 5. Nat. Commun. 7:10782 (2016)
40.
Kunath, N.* et al.: Ghrelin modulates encoding-related brain function without enhancing memory formation in humans. Neuroimage 142, 465-473 (2016)